Author:
Hoeh Benedikt,Preisser Felix,Wenzel Mike,Humke Clara,Wittler Clarissa,Köllermann Jens,Bodelle Boris,Bernatz Simon,Steuber Thomas,Tilki Derya,Graefen Markus,Karakiewicz Pierre I.,Becker Andreas,Kluth Luis A.,Chun Felix K.H.,Mandel Philipp
Reference29 articles.
1. N. Mottet Chair, P. Cornford Vice-chair, R.C.N. van den Bergh, E. Briers Patient Representative, M. De Santis, S. Fanti, et al. EAU guidelines for prostate cancer. Edn. presented at the EAU Annual Congress Amsterdam 2020. 2020. EAU Guidelines Office, Arnhem, The Netherlands.
2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019, AWMF Registernummer: 043/022OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/.
3. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;(4):CD006019.
4. Hajili T, Ohlmann CH, Linxweiler J, Niklas C, Janssen M, Siemer S, et al. Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up. BJU Int. 2019;123(1):58–64.
5. Zhang L, Zhao H, Wu B, Zha Z, Yuan J, Feng Y. The impact of neoadjuvant hormone therapy on surgical and oncological outcomes for patients with prostate cancer before radical prostatectomy: a systematic review and meta-analysis. Front Oncol. 2021;10:615801.